CLASS ACTION UPDATE for FGEN, PTON and PCT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / June 6, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
FGEN Shareholders Click Here: https://www.zlk.com/pslra-1/fibrogen-inc-information-request-form?prid=16595&wire=1
PTON Shareholders Click Here: https://www.zlk.com/pslra-1/peloton-interactive-inc-loss-submission-form?prid=16595&wire=1
PCT Shareholders Click Here: https://www.zlk.com/pslra-1/purecycle-technologies-inc-information-request-form?prid=16595&wire=1
* ADDITIONAL INFORMATION BELOW *
FibroGen, Inc. (NASDAQ:FGEN)
FGEN Lawsuit on behalf of: investors who purchased October 18, 2017 - April 6, 2021
Lead Plaintiff Deadline : June 11, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/fibrogen-inc-information-request-form?prid=16595&wire=1
According to the filed complaint, during the class period, FibroGen, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia certain safety analyses submitted in connection with CKD included post-hoc changes to the stratification factors; (ii) FibroGen's analyses with the pre-specified stratification factors result in higher hazard ratios (point estimates of relative risk) and 95% confidence intervals; (iii) based on these analyses the Company could not conclude that roxadustat reduces the risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa; (iv) as a result, the Company faced significant uncertainty that its NDA for roxadustat as a treatment for anemia of CKD would be approved by the FDA; and (v) as a result of the foregoing, Defendants' statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Peloton Interactive, Inc. (NASDAQ:PTON)
PTON Lawsuit on behalf of: investors who purchased September 11, 2020 - May 5, 2021
Lead Plaintiff Deadline : June 28, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/peloton-interactive-inc-loss-submission-form?prid=16595&wire=1
According to the filed complaint, during the class period, Peloton Interactive, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) in addition to the tragic death of a child, Peloton's Tread+ had caused a serious safety threat to children and pets as there were multiple incidents of injury to both; (2) safety was not a priority to Peloton as defendants were aware of serious injuries and death resulting from the Tread+, yet did not recall or suggest a halt of the use of the Tread+; (3) as a result of the safety concerns, the U.S. Consumer Product Safety Commission ("CPSC") declared that the Tread+ posed a serious risk to public health and safety and urgently recommended that consumers with small children cease using the Tread+; (4) the CPSC also found a safety threat to Tread+ users if they lost their balance; and (5) as a result of the foregoing, defendants' statements about Peloton's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
PureCycle Technologies, Inc. (NASDAQ:PCT)
PCT Lawsuit on behalf of: investors who purchased November 16, 2020 - May 5, 2021
Lead Plaintiff Deadline : July 12, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/purecycle-technologies-inc-information-request-form?prid=16595&wire=1
According to the filed complaint, during the class period, PureCycle Technologies, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the technology PureCycle licensed from Procter & Gamble is not proven and presents serious issues even at lab scale; (ii) the challenges posed by the availability and competition for the raw materials necessary to commercialize the licensed technology are significant; (iii) PureCycle's financial projections are baseless; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com:
https://www.accesswire.com/650582/CLASS-ACTION-UPDATE-for-FGEN-PTON-and-PCT-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders
